Otsuka Pharmaceutical

Otsuka Pharmaceutical, headquartered in Japan within the Pharmaceutical Preparation Manufacturing industry, reported Scope 1 emissions of 368,733,000 kg CO2e and Scope 2 emissions of 188,833,000 kg CO2e for 2024. In 2023, the company's Scope 1 emissions were 327,309,000 kg CO2e and Scope 2 emissions were 195,362,000 kg CO2e.

Otsuka Pharmaceutical has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and Scope 2 CO2 emissions by 2028, compared to a 2017 baseline. This target was accelerated in 2022 from a previous 2030 goal, and the reduction percentage was upgraded from 30%. The company is also working towards a long-term goal of achieving net-zero emissions across all business activities by 2050, as part of its "Net Zero" 2050 Environmental Vision. While Scope 3 emissions were reported for 2016 at 866,000,000 kg CO2e, comprehensive Scope 3 data is not consistently available for more recent years. Otsuka Pharmaceutical's near-term Science Based Targets Initiative (SBTi) target status is "Committed," cascaded from Otsuka Holdings Co., Ltd.